CO2022000502A2 - Sales de un compuesto, formas cristalinas de las sales y método de preparación y uso de las mismas - Google Patents
Sales de un compuesto, formas cristalinas de las sales y método de preparación y uso de las mismasInfo
- Publication number
- CO2022000502A2 CO2022000502A2 CONC2022/0000502A CO2022000502A CO2022000502A2 CO 2022000502 A2 CO2022000502 A2 CO 2022000502A2 CO 2022000502 A CO2022000502 A CO 2022000502A CO 2022000502 A2 CO2022000502 A2 CO 2022000502A2
- Authority
- CO
- Colombia
- Prior art keywords
- salts
- fluoro
- compound
- preparation
- crystalline forms
- Prior art date
Links
- 150000003839 salts Chemical class 0.000 title abstract 7
- 150000001875 compounds Chemical group 0.000 title abstract 3
- 239000013078 crystal Chemical group 0.000 title abstract 2
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 abstract 2
- AEFFENQISAXIKE-UHFFFAOYSA-N 5-fluoro-4-(7'-fluoro-2'-methylspiro[cyclopentane-1,3'-indole]-5'-yl)-N-[5-(1-methylpiperidin-4-yl)pyridin-2-yl]pyrimidin-2-amine Chemical compound CN1CCC(CC1)C1=CN=C(NC2=NC(=C(F)C=N2)C2=CC3=C(N=C(C)C33CCCC3)C(F)=C2)C=C1 AEFFENQISAXIKE-UHFFFAOYSA-N 0.000 abstract 1
- ZEDULSHOHJJAIZ-UHFFFAOYSA-N CN1CCC(CC1)C=1C=CC(=NC=1)NC1=NC=CC=N1 Chemical compound CN1CCC(CC1)C=1C=CC(=NC=1)NC1=NC=CC=N1 ZEDULSHOHJJAIZ-UHFFFAOYSA-N 0.000 abstract 1
- WNLRTRBMVRJNCN-UHFFFAOYSA-L adipate(2-) Chemical compound [O-]C(=O)CCCCC([O-])=O WNLRTRBMVRJNCN-UHFFFAOYSA-L 0.000 abstract 1
- 229940079593 drug Drugs 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 230000009246 food effect Effects 0.000 abstract 1
- 235000021471 food effect Nutrition 0.000 abstract 1
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 abstract 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-L succinate(2-) Chemical compound [O-]C(=O)CCC([O-])=O KDYFGRWQOYBRFD-UHFFFAOYSA-L 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201910542355 | 2019-06-21 | ||
| PCT/CN2020/097482 WO2020253875A1 (zh) | 2019-06-21 | 2020-06-22 | 一种化合物的盐、其晶型以及制备方法与应用 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CO2022000502A2 true CO2022000502A2 (es) | 2022-01-28 |
Family
ID=74040655
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CONC2022/0000502A CO2022000502A2 (es) | 2019-06-21 | 2022-01-21 | Sales de un compuesto, formas cristalinas de las sales y método de preparación y uso de las mismas |
Country Status (16)
| Country | Link |
|---|---|
| US (1) | US20220168302A1 (enExample) |
| EP (1) | EP3988546A4 (enExample) |
| JP (1) | JP2022538076A (enExample) |
| KR (1) | KR20220041090A (enExample) |
| CN (1) | CN115708409A (enExample) |
| AR (1) | AR119184A1 (enExample) |
| AU (1) | AU2020296048A1 (enExample) |
| BR (1) | BR112021025944A2 (enExample) |
| CA (1) | CA3144546A1 (enExample) |
| CL (1) | CL2021003438A1 (enExample) |
| CO (1) | CO2022000502A2 (enExample) |
| IL (1) | IL289231A (enExample) |
| MX (1) | MX2022000051A (enExample) |
| PH (1) | PH12021553151A1 (enExample) |
| WO (1) | WO2020253875A1 (enExample) |
| ZA (1) | ZA202200964B (enExample) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2022042738A1 (zh) * | 2020-08-31 | 2022-03-03 | 甘李药业股份有限公司 | 一种含cdk4/6抑制剂的药物组合物 |
| US20250332167A1 (en) * | 2021-05-17 | 2025-10-30 | Gan & Lee Pharmaceuticals Co., Ltd. | Pharmaceutical use of cdk 4/6 inhibitor |
| EP4696689A1 (en) * | 2023-04-04 | 2026-02-18 | Suzhou Kintor Pharmaceuticals, Inc. | Salt form and crystal form of chiral heterocyclic compound having hedgehog pathway antagonist activity |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SK9742002A3 (en) * | 2000-01-07 | 2003-02-04 | Transform Pharmaceuticals Inc | High-throughput formation, identification, and analysis of diverse solid-forms |
| CN106810536A (zh) * | 2015-11-30 | 2017-06-09 | 甘李药业股份有限公司 | 一种蛋白激酶抑制剂及其制备方法和医药用途 |
-
2020
- 2020-06-18 AR ARP200101717A patent/AR119184A1/es not_active Application Discontinuation
- 2020-06-22 WO PCT/CN2020/097482 patent/WO2020253875A1/zh not_active Ceased
- 2020-06-22 EP EP20827805.1A patent/EP3988546A4/en not_active Withdrawn
- 2020-06-22 PH PH1/2021/553151A patent/PH12021553151A1/en unknown
- 2020-06-22 AU AU2020296048A patent/AU2020296048A1/en not_active Withdrawn
- 2020-06-22 KR KR1020227002390A patent/KR20220041090A/ko not_active Withdrawn
- 2020-06-22 CA CA3144546A patent/CA3144546A1/en active Pending
- 2020-06-22 JP JP2021576253A patent/JP2022538076A/ja active Pending
- 2020-06-22 US US17/596,721 patent/US20220168302A1/en not_active Abandoned
- 2020-06-22 MX MX2022000051A patent/MX2022000051A/es unknown
- 2020-06-22 BR BR112021025944A patent/BR112021025944A2/pt unknown
- 2020-06-22 CN CN202080045649.9A patent/CN115708409A/zh active Pending
-
2021
- 2021-12-21 IL IL289231A patent/IL289231A/en unknown
- 2021-12-21 CL CL2021003438A patent/CL2021003438A1/es unknown
-
2022
- 2022-01-20 ZA ZA2022/00964A patent/ZA202200964B/en unknown
- 2022-01-21 CO CONC2022/0000502A patent/CO2022000502A2/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| CA3144546A1 (en) | 2020-12-24 |
| EP3988546A4 (en) | 2023-05-17 |
| EP3988546A1 (en) | 2022-04-27 |
| AR119184A1 (es) | 2021-12-01 |
| KR20220041090A (ko) | 2022-03-31 |
| MX2022000051A (es) | 2022-05-24 |
| US20220168302A1 (en) | 2022-06-02 |
| AU2020296048A1 (en) | 2022-02-10 |
| BR112021025944A2 (pt) | 2022-02-08 |
| CN115708409A (zh) | 2023-02-21 |
| PH12021553151A1 (en) | 2022-07-25 |
| WO2020253875A1 (zh) | 2020-12-24 |
| CL2021003438A1 (es) | 2022-09-30 |
| JP2022538076A (ja) | 2022-08-31 |
| IL289231A (en) | 2022-02-01 |
| ZA202200964B (en) | 2022-08-31 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ECSP21044734A (es) | FORMAS POLIMÓRFICAS NOVEDOSAS DE UN INHIBIDOR DE TGFBeta | |
| ECSP078030A (es) | Formas cristalinas y otras formas de las sales de ácido láctico de 4-amino-5-fluoro-3-[6-(4-metilpiperazin -1-il)-1h-bencimidazol-2 -il]-1h-quinolin-2-ona | |
| UY38001A (es) | Compuestos que inhiben las proteínas ras mutantes g12c | |
| CL2020001762A1 (es) | Formas cristalinas del derivado de 4-pirimidinsulfamida de aprocitentán. (divisional solicitud 201902464) | |
| MX2018015630A (es) | Pirimidina-2-ilamino-1h-pirazoles como inhibidores de lrrk2 para el uso en el tratamiento de trastornos neurogenerativos. | |
| CY1122468T1 (el) | Κρυσταλλικη μορφη διθειικου αναστολεα κινασης jak και μια μεθοδος παρασκευης αυτου | |
| SG10201906942PA (en) | Piperidine cxcr7 receptor modulators | |
| ECSP16005566A (es) | Sulfonamidas como moduladores de canales de sodio | |
| CL2020003101A1 (es) | Sales de sepiapterina farmacéuticamente aceptables. | |
| WO2016105564A8 (en) | Quinazoline derivatives used to treat hiv | |
| EA201992501A1 (ru) | Соль соединения производного аминопиридина, ее кристаллическая форма и способ получения | |
| CL2021003438A1 (es) | Sales de un compuesto, formas cristalinas de las sales y método de preparación y uso de las mismas | |
| AU2019333310A8 (en) | Salts and crystal forms of GABAA positive allosteric modulator | |
| HK1222396A1 (zh) | 作为选择性蛋白质激酶抑制剂之苯并咪唑衍生物 | |
| PH12019502562B1 (en) | N-substituted indole derivatives | |
| MX2018013742A (es) | Formas cristalinas de crisaborol en forma libre, metodo de preparacion y uso de las mismas. | |
| MX2019012967A (es) | Cristal de base libre de derivados benzofurano y metodo de preparacion. | |
| AR115303A1 (es) | Moduladores de calpaína y usos terapéuticos de los mismos | |
| MX2021012248A (es) | Polimorfos de voruciclib y metodos de elaboracion y uso de los mismos. | |
| MX386263B (es) | Cristal de derivado de heterociclideno acetamida | |
| EP4295916A3 (en) | Salts of 4-amino-n-(1-((3-chloro-2-fluorophenyl)amino)-6-methylisoquinolin-5-yl)thieno[3,2-d]pyrimidine-7-carboxamide, and crystalline forms thereof | |
| AR109168A1 (es) | Sales de derivados de 2,6-dimetilpirimidona y sus usos | |
| AU2018264313A1 (en) | Indolizine derivatives and application thereof in medicine | |
| MX2018013729A (es) | Forma cristalina nueva de dapagliflozina y metodo de preparacion y uso de la misma. | |
| PE20200887A1 (es) | Forma a-i de monoacetato de (s)-7-(4-(1-(metilsulfonil)piperidin-4-il)fenil)-n-(morfolin-2-ilmetil)pirido[3,4-b]pirazin-5-amina |